<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767519</url>
  </required_header>
  <id_info>
    <org_study_id>191622-125</org_study_id>
    <nct_id>NCT01767519</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the efficacy and safety of BOTOX® or Solifenacin in patients with
      overactive bladder (OAB) and urinary incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1</measure>
    <time_frame>Study Baseline, Week 12</time_frame>
    <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to the study visit in Treatment Cycle 1. The number of incontinence episodes are averaged daily during this period. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With 100% Reduction in Incontinence Episodes in Treatment Cycle 1</measure>
    <time_frame>Study Baseline, Week 12</time_frame>
    <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to the study visit in Treatment Cycle 1. The number of incontinence episodes are averaged daily during this period and compared to baseline to determine 100% reduction in episodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a Positive Response on the Single-Item Treatment Benefit Scale During Treatment Cycle 1</measure>
    <time_frame>Week 12</time_frame>
    <description>A positive treatment response on the Treatment Benefit Scale is a score of either 1 or 2, representing 'greatly improved' or 'improved.'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Number of Micturition Episodes in Treatment Cycle 1</measure>
    <time_frame>Study Baseline, Week 12</time_frame>
    <description>The number of micturition episodes (the number of times a patient urinates into the toilet) in Treatment Cycle 1 was recorded by the patient in a bladder diary during 3 consecutive days in the week prior to the visit. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Number of Nocturia Episodes in Treatment Cycle 1</measure>
    <time_frame>Study Baseline, Week 12</time_frame>
    <description>Nocturia episodes are measured over a 3 day diary prior to each visit in Treatment Cycle 1. A nocturia episode is a void (urinating into the toilet) that interrupts one's sleep. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Role Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1</measure>
    <time_frame>Study Baseline, Week 12</time_frame>
    <description>The King's Health Questionnaire is a disease-specific questionnaire that measures the quality of life of patients with urinary incontinence. The questionnaire consists of 7 domains, including the role limitations domain. Domain scores range from 0 to 100, with a lower score indicating a preferable health status. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Study Baseline in the Social Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1</measure>
    <time_frame>Study Baseline, Week 12</time_frame>
    <description>The King's Health Questionnaire is a disease-specific questionnaire that measures the quality of life of patients with urinary incontinence. The questionnaire consists of 7 domains, including the social limitations domain. Domain scores range from 0 to 100, with a lower score indicating a preferable health status. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>BOTOX®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>solifenacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BOTOX®</intervention_name>
    <description>BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.</description>
    <arm_group_label>BOTOX®</arm_group_label>
    <arm_group_label>solifenacin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>onabotulinumtoxinA</other_name>
    <other_name>botulinum toxin Type A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin</intervention_name>
    <description>Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.</description>
    <arm_group_label>solifenacin</arm_group_label>
    <other_name>Vesicare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox placebo (normal saline)</intervention_name>
    <description>Botox placebo (normal saline) intradetrusor injection at Day 1.</description>
    <arm_group_label>solifenacin</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>solifenacin placebo</intervention_name>
    <description>Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.</description>
    <arm_group_label>BOTOX®</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms of Overactive Bladder (OAB) (frequency/urgency) with urinary incontinence for
             at least 6 months

          -  Inadequate response or limiting side effects with anticholinergics for the treatment
             of OAB

        Exclusion Criteria:

          -  Overactive Bladder caused by neurological condition

          -  Patient has predominance of stress incontinence

          -  Use of anticholinergics or other medications to treat OAB symptoms in the 7 days prior
             to screening

          -  Previous use of solifenacin

          -  History or evidence of pelvic or urological abnormality

          -  Previous use of any botulinum toxin of any serotype for any urological condition

          -  Previous use of any botulinum toxin of any serotype for any non-urological condition
             within 12 weeks of randomization

          -  Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague 6</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2013</study_first_posted>
  <results_first_submitted>October 21, 2015</results_first_submitted>
  <results_first_submitted_qc>December 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2016</results_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participant Flow is for Treatment cycle 1, which is the double-blind portion of the study and includes the primary timepoint.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BOTOX®</title>
          <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
        </group>
        <group group_id="P2">
          <title>Solifenacin</title>
          <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BOTOX®</title>
          <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
        </group>
        <group group_id="B2">
          <title>Solifenacin</title>
          <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="356"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1</title>
        <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to the study visit in Treatment Cycle 1. The number of incontinence episodes are averaged daily during this period. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
        <time_frame>Study Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>BOTOX®</title>
            <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin</title>
            <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1</title>
          <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to the study visit in Treatment Cycle 1. The number of incontinence episodes are averaged daily during this period. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
          <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
          <units>Incontinence Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" spread="3.206"/>
                    <measurement group_id="O2" value="5.23" spread="3.333"/>
                    <measurement group_id="O3" value="4.38" spread="2.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Study Baseline at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.10" spread="2.799"/>
                    <measurement group_id="O2" value="-2.66" spread="3.059"/>
                    <measurement group_id="O3" value="-0.98" spread="2.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With 100% Reduction in Incontinence Episodes in Treatment Cycle 1</title>
        <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to the study visit in Treatment Cycle 1. The number of incontinence episodes are averaged daily during this period and compared to baseline to determine 100% reduction in episodes.</description>
        <time_frame>Study Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>BOTOX®</title>
            <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin</title>
            <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With 100% Reduction in Incontinence Episodes in Treatment Cycle 1</title>
          <description>Urinary incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary in the 3 consecutive days prior to the study visit in Treatment Cycle 1. The number of incontinence episodes are averaged daily during this period and compared to baseline to determine 100% reduction in episodes.</description>
          <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="24.5"/>
                    <measurement group_id="O3" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a Positive Response on the Single-Item Treatment Benefit Scale During Treatment Cycle 1</title>
        <description>A positive treatment response on the Treatment Benefit Scale is a score of either 1 or 2, representing ‘greatly improved’ or ‘improved.’</description>
        <time_frame>Week 12</time_frame>
        <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>BOTOX®</title>
            <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin</title>
            <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Positive Response on the Single-Item Treatment Benefit Scale During Treatment Cycle 1</title>
          <description>A positive treatment response on the Treatment Benefit Scale is a score of either 1 or 2, representing ‘greatly improved’ or ‘improved.’</description>
          <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" lower_limit="62.9" upper_limit="78.7"/>
                    <measurement group_id="O2" value="74.0" lower_limit="66.1" upper_limit="80.9"/>
                    <measurement group_id="O3" value="44.8" lower_limit="31.7" upper_limit="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Number of Micturition Episodes in Treatment Cycle 1</title>
        <description>The number of micturition episodes (the number of times a patient urinates into the toilet) in Treatment Cycle 1 was recorded by the patient in a bladder diary during 3 consecutive days in the week prior to the visit. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
        <time_frame>Study Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>BOTOX®</title>
            <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin</title>
            <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Number of Micturition Episodes in Treatment Cycle 1</title>
          <description>The number of micturition episodes (the number of times a patient urinates into the toilet) in Treatment Cycle 1 was recorded by the patient in a bladder diary during 3 consecutive days in the week prior to the visit. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
          <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
          <units>Micturition Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.74" spread="2.520"/>
                    <measurement group_id="O2" value="10.40" spread="2.665"/>
                    <measurement group_id="O3" value="10.18" spread="2.491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Study Baseline at Wk 12 (N=135,144,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.40" spread="2.827"/>
                    <measurement group_id="O2" value="-2.03" spread="2.833"/>
                    <measurement group_id="O3" value="-0.87" spread="2.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Number of Nocturia Episodes in Treatment Cycle 1</title>
        <description>Nocturia episodes are measured over a 3 day diary prior to each visit in Treatment Cycle 1. A nocturia episode is a void (urinating into the toilet) that interrupts one's sleep. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
        <time_frame>Study Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>BOTOX®</title>
            <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin</title>
            <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Number of Nocturia Episodes in Treatment Cycle 1</title>
          <description>Nocturia episodes are measured over a 3 day diary prior to each visit in Treatment Cycle 1. A nocturia episode is a void (urinating into the toilet) that interrupts one's sleep. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
          <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
          <units>Nocturia Episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="1.159"/>
                    <measurement group_id="O2" value="2.04" spread="1.083"/>
                    <measurement group_id="O3" value="1.98" spread="0.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Study Baseline at Wk 12 (N=135,144,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="1.195"/>
                    <measurement group_id="O2" value="-0.49" spread="1.133"/>
                    <measurement group_id="O3" value="-0.23" spread="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Role Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1</title>
        <description>The King's Health Questionnaire is a disease-specific questionnaire that measures the quality of life of patients with urinary incontinence. The questionnaire consists of 7 domains, including the role limitations domain. Domain scores range from 0 to 100, with a lower score indicating a preferable health status. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
        <time_frame>Study Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>BOTOX®</title>
            <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin</title>
            <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Role Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1</title>
          <description>The King's Health Questionnaire is a disease-specific questionnaire that measures the quality of life of patients with urinary incontinence. The questionnaire consists of 7 domains, including the role limitations domain. Domain scores range from 0 to 100, with a lower score indicating a preferable health status. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
          <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.09" spread="24.281" lower_limit="61.1" upper_limit="77.2"/>
                    <measurement group_id="O2" value="72.11" spread="26.581" lower_limit="51.5" upper_limit="68.0"/>
                    <measurement group_id="O3" value="81.36" spread="20.781" lower_limit="39.0" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Study Baseline at Wk 12 (N=135,145,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.0" spread="33.259" lower_limit="52.0" upper_limit="69.0"/>
                    <measurement group_id="O2" value="-23.79" spread="31.899" lower_limit="49.5" upper_limit="66.1"/>
                    <measurement group_id="O3" value="-17.25" spread="29.033" lower_limit="29.1" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Study Baseline in the Social Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1</title>
        <description>The King's Health Questionnaire is a disease-specific questionnaire that measures the quality of life of patients with urinary incontinence. The questionnaire consists of 7 domains, including the social limitations domain. Domain scores range from 0 to 100, with a lower score indicating a preferable health status. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
        <time_frame>Study Baseline, Week 12</time_frame>
        <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
        <group_list>
          <group group_id="O1">
            <title>BOTOX®</title>
            <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin</title>
            <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Study Baseline in the Social Limitations Domain on the King's Health Questionnaire in Treatment Cycle 1</title>
          <description>The King's Health Questionnaire is a disease-specific questionnaire that measures the quality of life of patients with urinary incontinence. The questionnaire consists of 7 domains, including the social limitations domain. Domain scores range from 0 to 100, with a lower score indicating a preferable health status. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.</description>
          <population>Intent-to-Treat: includes all patients according to the group to which they are randomized</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Study Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.66" spread="21.442" lower_limit="61.1" upper_limit="77.2"/>
                    <measurement group_id="O2" value="56.22" spread="22.708" lower_limit="51.5" upper_limit="68.0"/>
                    <measurement group_id="O3" value="62.57" spread="22.551" lower_limit="39.0" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Study Baseline at Wk 12 (N=135,145,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.46" spread="21.906" lower_limit="52.0" upper_limit="69.0"/>
                    <measurement group_id="O2" value="-12.70" spread="21.361" lower_limit="49.5" upper_limit="66.1"/>
                    <measurement group_id="O3" value="-7.60" spread="21.667" lower_limit="29.1" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The safety population includes all patients who received at least 1 dose of study medication. The safety population is used to assess adverse events and serious adverse events. Adverse events and serious adverse events are displayed for the placebo-controlled treatment Cycle 1.</desc>
      <group_list>
        <group group_id="E1">
          <title>BOTOX®</title>
          <description>Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.</description>
        </group>
        <group group_id="E2">
          <title>Solifenacin</title>
          <description>Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Polysubstance dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <description>FEMALE ONLY</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="123"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Residual urine volume</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

